Advertisement

Topics

ReNeuron shares spike 20% after it provides encouraging update to phase II eye disease trial

07:52 EST 20 Feb 2019 | Proactive Investors

The first three patients in a group taking part in the phase II portion of the study were able on average able to read an additional three lines of on the standard ETDRS eye chart after receiving treatment

Original Article: ReNeuron shares spike 20% after it provides encouraging update to phase II eye disease trial

NEXT ARTICLE

More From BioPortfolio on "ReNeuron shares spike 20% after it provides encouraging update to phase II eye disease trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...